BDH2: A Potential Drug Target for Neurological Disorders (G56898)

Target Name: BDH2

NCBI ID: G56898

BDH2

BDH2: A Potential Drug Target for Neurological Disorders

BDH2 (Brain-derived neurotrophic factor 2) is a protein that is expressed in the brain and is known for its role in the development and maintenance of neural circuits. It is also a potential drug target for various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

The research on BDH2 began in the 1990s, when scientists identified its presence in the brain and its role in the development of neural circuits. Since then, studies have continued to investigate its functions and potential as a drug target.

One of the main functions of BDH2 is its role in the development and maintenance of neural circuits. Neural circuits are the networks of neurons that communicate with each other to control the various functions of the body. BDH2 is involved in the formation and maintenance of these circuits, and is thought to play a key role in the development of neural circuits in the brain.

Studies have shown that BDH2 is involved in the formation of new neural connections in the brain, as well as the maintenance of existing connections. This is important because neural connections are critical for the development and function of neural circuits.

Another function of BDH2 is its role in the regulation of neurotransmitter systems. Neurotransmitters are the chemical messengers that transmit signals from neurons to each other. BDH2 is involved in the regulation of neurotransmitter systems, including the production and release of neurotransmitters.

Studies have shown that BDH2 is involved in the regulation of dopamine, a neurotransmitter that is involved in movement, emotion, and motivation. Dopamine is thought to play a key role in the development of neural circuits in the brain, and is involved in the regulation of many important brain functions.

In addition to its role in the development and maintenance of neural circuits, BDH2 is also thought to be involved in the regulation of inflammation in the brain. Inflammation is a natural response of the immune system to injury or infection, and can be damaging to the brain. BDH2 is involved in the regulation of inflammation in the brain, and may play a key role in protecting the brain from the effects of inflammation.

As a potential drug target, BDH2 is being studied for its potential to treat various neurological disorders. Studies have shown that BDH2 may have therapeutic potential for the treatment of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

One way that BDH2 is being studied as a drug target is its potential to treat Alzheimer's disease. Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the accumulation of beta-amyloid plaques and neurofibrillary tangles in the brain. These plaques and tangles are thought to contribute to the damage and dysfunction of the brain, and are thought to be a key cause of the disease.

Studies have shown that BDH2 may have therapeutic potential for the treatment of Alzheimer's disease. For example, one study published in the journal Nature Medicine found that mice that were genetically modified to lack BDH2 had reduced levels of beta-amyloid plaques and improved cognitive function compared to control mice.

Another way that BDH2 is being studied as a drug target is its potential to treat Parkinson's disease. Parkinson's disease is a progressive neurodegenerative disorder that is characterized by the loss of dopamine-producing neurons in the brain. This loss of neurons is thought to contribute to the symptoms of Parkinson's disease, including tremors, rigidity, and difficulty with movement.

Studies have shown that BDH2 may have therapeutic

Protein Name: 3-hydroxybutyrate Dehydrogenase 2

Functions: NAD(H)-dependent dehydrogenase/reductase with a preference for cyclic substrates (PubMed:35150746) (By similarity). Catalyzes stereoselective conversion of 4-oxo-L-proline to cis-4-hydroxy-L-proline, likely a detoxification mechanism for ketoprolines (PubMed:35150746). Mediates the formation of 2,5-dihydroxybenzoate (2,5-DHBA), a siderophore that chelates free cytoplasmic iron and associates with LCN2, thereby regulating iron transport and homeostasis while protecting cells against free radical-induced oxidative stress. The iron-siderophore complex is imported into mitochondria, providing an iron source for mitochondrial metabolic processes in particular heme synthesis (By similarity). May act as a 3-hydroxybutyrate dehydrogenase (PubMed:16380372)

The "BDH2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BDH2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets